SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Podcast
Billions More in M&A, Another Bidding War and More FDA Drama
Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel. Meanwhile, Rick Pazdur has taken the helm at CDER while tensions run high between FDA Commissioner Marty Makary and Health Secretary RFK Jr.
November 19, 2025
 · 
1 min read
 · 
Heather McKenzie
Illustration showing set of science speech bubbles
Career Advice
Science Isn’t Complete Until It’s Clear: Communication Key to Research Process
Communication must be viewed as more than the last step of the research process. It is the structure that makes scientific work clear, trusted and remembered.
November 19, 2025
 · 
5 min read
 · 
Manali Shah
Illustration showing two connected arrows going off in different directions
Career Advice
Fork in the Road: What To Do When Your Biopharma Career Goes Off Track
What should you do when belief in the mission remains, but the career path doesn’t?
November 19, 2025
 · 
4 min read
 · 
Angela Justice
Retro 3d magazine collage image of arms collecting coins piggy money box isolated checkered blue color background.
Drug pricing
As GLP-1s Hit Bargain Bin Prices, What’s the Future of the Obesity Market?
Novo Nordisk goes “on the offensive” following Trump deal that also included rival Eli Lilly, putting an exclamation point on rapidly declining GLP-1 drug prices. Experts say the unusual situation makes it hard to predict what’s next.
November 19, 2025
 · 
5 min read
 · 
Annalee Armstrong
Relay race. Concept of teamwork. working together of business. Vector illustration
Mergers & acquisitions
Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions
Drug candidates don’t usually move among Big Pharma, but these five biotechs helped facilitate such hand-offs, scooping up assets from one pharma on the cheap before being bought out for billions by another.
November 19, 2025
 · 
9 min read
 · 
Tristan Manalac
White plane in blue sky flies above clouds towards hot sun. Vector background
Approvals
Arrowhead Secures Maiden Approval, First FDA Nod for Rare Genetic Metabolic Disorder
The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta caused its own stock to drop during the gene therapy maker’s safety troubles this summer.
November 18, 2025
 · 
2 min read
 · 
Heather McKenzie
Richard Pazdur
FDA
Makary Got His Man in Pazdur—But Can He Last as CDER Director?
A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the “ideal fit” to stabilize the agency. And, according to one ex-FDA official, if his CBER counterpart Vinay Prasad tries to supersede Pazdur’s authority, “there will be hell to pay.”
November 18, 2025
 · 
6 min read
 · 
Heather McKenzie
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Cardiovascular disease
Merck Extends Winrevair’s Win Streak With New Mid-Stage Data in Type of Hypertension
Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary hypertension, an indication that, according to BMO Capital Markets, has few treatment options.
November 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Pruning tree branches. Gloved hands hold a branch and cutting shears, the gardener takes care of the park. Vector illustration.
Antibody-drug conjugate (ADC)
Genmab Prunes Another ADC From $1.8B ProfoundBio Acquisition
Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in late-stage studies for ovarian and endometrial cancer.
November 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS